After Roche’s exit, Blueprint passes Gavreto on to Rigel

Almost a year to the day after Roche pulled out a partnership on its underperforming cancer therapy Gavreto, Blueprint Medicines has sold US commercial rights to the drug

Chinese biotech Sironax raises $200m for RIPK1 pipeline

Beijing biotech Sironax has closed a whopping $200 million second-round financing that shows investors still have a desire to back companies working on RIPK1 inhibitors despite setbacks for

Lilly cuts a $960m deal with Rigel on RIP kinase

Eli Lilly has become the latest drugmaker to have a go at developing RIP kinase inhibitors, a new class of drugs with potential in autoimmune and inflammatory disease, paying $125 million u

Sobi gets EU nod for Doptelet in rare blood disorder ITP

Sweden’s Sobi has secured EU approval for Doptelet in primary chronic immune thrombocytopenia (ITP), an indication that the company expects to accelerate sales of the drug.

Scotland backs Roche’s Rozlytrek for ROS1 lung cancer

The Scottish Medicines Consortium (SMC) has given a green light to Roche’s Rozlytrek for a rare form of lung cancer, almost seven months after NICE backed the drug in England.

Novartis’ Mayzent, Roche’s Polivy head latest crop of CHMP a...